SaniMed Science Group shares insights following Founder Jim Wu, M.D., MBA’s completion of the MIT Sloan Executive Program in Artificial Intelligence in Pharma and Biotech. The program deepened strategic understanding of AI-driven discovery, clinical development, regulatory readiness, and commercialization, reinforcing SaniMed’s mission to accelerate global MedTech and Biotech innovation across the U.S., China, and Europe through responsible, scalable AI solutions.